resources

The Challenge:
One of the most common challenges in immuno-oncology is identifying the indications and patient populations that would benefit from a specific therapy, especially on top of Standard of Care (SOC) treatments. Our platform tackled this challenge of indication prioritization and patient stratification for a combination of a specific target (A) with an anti-PDX drug that one of our big pharma clients was considering.

The Strategy:

Our disease models capture cell-specific gene expression of multiple cell types and subsets in high resolution. Furthermore, they can predict the specific Tumor Microenvironment (TME) subtype of each sample, based on cell composition estimation, thereby stratifying each oncological indication to distinct TME models.

This collection of models and model TME subtypes was used to:

a. Predict in which indications and TME subtypes per indication the cellular localization of the targets aligns with the therapeutic hypothesis.
b. Overlay the client’s clinical trial data onto the disease model and predict whether target-A is associated with a resistance to the anti-PDx drug.